Everything is strategic. Every stroke of EPGL's and the NYSE Company's CEO's pen is done with a very specific strategy in mind.
Remember, the other company has shareholders as well. Shareholders that aren't rinky dink pennystock traders. Big money shareholders. Investment firms, analysts, all sorts of funds, you name it.
If you can imagine all of the silly and ridiculous emails that EPGL gets daily from silly penny stock investors, imagine what kind of emails the NYSE Company gets from their professional ones. Especially with the current market environment in the biotech field. Those investors, in all likelihood, have the voting power to remove management. And that is something that is always on his or her mind.
The NYSE's Company will want to release the info sooner rather than later. And you can bet that their timing will be pin point perfect, at a time where it benefits the CEO as much as the shareholder. The timing doesn't have to be when the product is ready to go to market. All it needs is for it's partnership with EPGL, which is, in all likelihood, continuing to evolve, to have all their i's dotted and t's crossed. And to have all the necessary and relevant IP locked up with the USPTO.
So, with all that being said, in my opinion, we could, very possibly, see the announcement by the end of the 2nd quarter. If not then, sometime after Labor day when summer ends. Basically within roughly 2-4 months. Perfect amount of time to continue acquiring shares for me.
